Fortitude Family Office’s Catalyst Pharmaceutical CPRX Stock Holding History

Fortitude Family Office’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.43K	Buy	141 +35	+33%	+$1.03K	﹤0.01%	1135
2026 Q1	$2.63K	Hold	106	–	–	﹤0.01%	1184
2025 Q4	$2.47K	Hold	106	–	–	﹤0.01%	1088
2025 Q3	$2.09K	Hold	106	–	–	﹤0.01%	1200
2025 Q2	$2.3K	Sell	106 -11	-9%	-$260	﹤0.01%	1125
2025 Q1	$2.84K	Hold	117	–	–	﹤0.01%	858
2024 Q4	$2.44K	Hold	117	–	–	﹤0.01%	1002
2024 Q3	$2.33K	Hold	117	–	–	﹤0.01%	973
2024 Q2	$1.81K	Hold	117	–	–	﹤0.01%	817
2024 Q1	$1.86K	Hold	117	–	–	﹤0.01%	833
2023 Q4	$1.97K	Buy	+117	New	+$1.6K	﹤0.01%	872

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fortitude Family Office's CPRX Position: Q2 2026 in Review

Fortitude Family Office increased its Catalyst Pharmaceutical (CPRX) stake by 33% in Q2 2026, buying an estimated $1.03K and bringing the position to 141 shares worth $4.43K. The position accounts for ﹤0.01% of the portfolio, ranked #1135.

Fortitude Family Office first reported a position in CPRX in Q4 2023 and has held it in 11 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Fortitude Family Office held 141 shares of Catalyst Pharmaceutical worth $4.43K as of Q2 2026.
Fortitude Family Office bought 35 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.03K.
Catalyst Pharmaceutical made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1135 holding.
Fortitude Family Office first reported a position in Catalyst Pharmaceutical in Q4 2023 and has held it in 11 quarters since.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.